Literature DB >> 27026349

Transplantation: BENEFIT of belatacept: kidney transplantation moves forward.

Maarten Naesens1, Olivier Thaunat2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27026349     DOI： 10.1038/nrneph.2016.34

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Summary of the US FDA approval of belatacept.

Authors:  P Archdeacon; C Dixon; O Belen; R Albrecht; J Meyer
Journal:  Am J Transplant       Date:  2012-02-15       Impact factor: 8.086

Review 2.  Prevention of cardiovascular disease in adult recipients of kidney transplants.

Authors:  Alan G Jardine; Robert S Gaston; Bengt C Fellstrom; Hallvard Holdaas
Journal:  Lancet       Date:  2011-10-15       Impact factor: 79.321

Review 3.  The elephant in the room: failings of current clinical endpoints in kidney transplantation.

Authors:  J D Schold; B Kaplan
Journal:  Am J Transplant       Date:  2010-05       Impact factor: 8.086

4.  Long-term renal allograft survival in the United States: a critical reappraisal.

Authors:  K E Lamb; S Lodhi; H-U Meier-Kriesche
Journal:  Am J Transplant       Date:  2010-10-25       Impact factor: 8.086

Review 5.  Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies.

Authors:  Philip F Halloran; Jeff P Reeve; Andre B Pereira; Luis G Hidalgo; Konrad S Famulski
Journal:  Kidney Int       Date:  2013-08-21       Impact factor: 10.612

6.  A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).

Authors:  A Durrbach; J M Pestana; T Pearson; F Vincenti; V D Garcia; J Campistol; M del Carmen Rial; S Florman; A Block; G Di Russo; J Xing; P Garg; J Grinyó
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

7.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

8.  Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.

Authors:  L Rostaing; F Vincenti; J Grinyó; K M Rice; B Bresnahan; S Steinberg; S Gang; L E Gaite; M-C Moal; G A Mondragón-Ramirez; J Kothari; L Pupim; C P Larsen
Journal:  Am J Transplant       Date:  2013-09-18       Impact factor: 8.086

9.  Belatacept and Long-Term Outcomes in Kidney Transplantation.

Authors:  Flavio Vincenti; Lionel Rostaing; Joseph Grinyo; Kim Rice; Steven Steinberg; Luis Gaite; Marie-Christine Moal; Guillermo A Mondragon-Ramirez; Jatin Kothari; Martin S Polinsky; Herwig-Ulf Meier-Kriesche; Stephane Munier; Christian P Larsen
Journal:  N Engl J Med       Date:  2016-01-28       Impact factor: 91.245

10.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.

Authors:  Gilda Piaggio; Diana R Elbourne; Stuart J Pocock; Stephen J W Evans; Douglas G Altman
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272
  10 in total
  5 in total

1.  Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.

Authors:  Michael S Mulvihill; Kannan P Samy; Qimeng A Gao; Robin Schmitz; Robert P Davis; Brian Ezekian; Francis Leopardi; Mingqing Song; Tam How; Kyha Williams; Andrew Barbas; Bradley Collins; Allan D Kirk
Journal:  Am J Transplant       Date:  2019-04-12       Impact factor: 8.086

Review 2.  Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation.

Authors:  Maarten Naesens; Alexandre Loupy; Luuk Hilbrands; Rainer Oberbauer; Maria Irene Bellini; Denis Glotz; Josep Grinyó; Uwe Heemann; Ina Jochmans; Liset Pengel; Marlies Reinders; Stefan Schneeberger; Klemens Budde
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

Review 3.  Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation.

Authors:  Daniel Seron; Marion Rabant; Jan Ulrich Becker; Candice Roufosse; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Fritz Diekmann; Denis Glotz; Luuk Hilbrands; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

4.  Ex Vivo Generation of Donor Antigen-Specific Immunomodulatory Cells: A Comparison Study of Anti-CD80/86 mAbs and CTLA4-lg Costimulatory Blockade.

Authors:  M Watanabe; Makiko Kumagai-Braesch; M Yao; S Thunberg; D Berglund; F Sellberg; C Jorns; S Lind Enoksson; J Henriksson; T Lundgren; M Uhlin; E Berglund; B-G Ericzon
Journal:  Cell Transplant       Date:  2018-09-27       Impact factor: 4.064

5.  Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the European Medicines Agency by the European Society for Organ Transplantation.

Authors:  Maarten Naesens; Stefan Schneeberger
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.